Novel molecules represent the exciting landscape in drug discovery. Such short chains of building units present significant potential for engaging previously pathways involved in multiple diseases. Early Nexaph peptides investigations demonstrate they can achieve selective affinity and exhibit desirable pharmacokinetic characteristics, paving ways